Cite
HARVARD Citation
Modak, S. et al. (2017). Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatric blood & cancer. 64 (8), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Modak, S. et al. (2017). Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study. Pediatric blood & cancer. 64 (8), p. n/a. [Online].